Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

CURRICULUM VITAE

Andres Jose Yarur MD
Assistant Professor
Department of Medicine
Division of Gastroenterology

OFFICE ADDRESS:
Froedtert Hospital
9200 W Wisconsin Ave
Milwaukee, WI 53226

EDUCATION:
03/31/2005 Licenciado en Medicina, Univesidad Mayor, Santiago, Chile
12/21/2006 MD, Universidad Mayor, Santiago, Chile

POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS:
2007 Diploma, Internal Medicine, University of Chile, Santiago, Chile
06/2008 - 06/2011 Residency, Internal Medicine, Jackson Memorial Hospital-University of Miami, Miami, FL
07/2011 - 06/2014 Fellowship, Gastroenterology, Jackson Memorial Hospital-University of Miami, Miami, FL
2015 Fellowship, Inflammatory Bowel Disease, University of Chicago, Chicago, IL

FACULTY APPOINTMENTS:
2015 - Present Assistant Professor of Medicine, Medical College of Wisconsin, Milwaukee, WI

ADMINISTRATIVE APPOINTMENTS:
2015 - Present Director, Inflammatory Bowel Disease program, Zablocki VA Medical Center, Milwaukee, WI

HOSPITAL STAFF PRIVILEGES:
09/01/2015 - Present Director of the IBD Program, Zablocki VA Medical Center, 5000 W. National Ave., Milwaukee, WI 53295
09/01/2015 - Present Assistant Professor, Medicine, Gastroenterology & Hepatology, Froedtert Hospital, 9200 W. Wisconsin Ave., Milwaukee, WI 53226

AWARDS AND HONORS:
2006 Medical Student Award for Excellence in Research, Universidad Mayor
2006 Universidad Mayor's Board of Directors award for outstanding performance
2011 - 2013 IBD Abstract Award, American College of Gastroenterology
2011 - 2013 Recipient of the Robert & Sissy Feltman endowed educational grant
2012 Honored membership in the Alpha Omega Alpha medical society
2012 - 2013 Award for study presentation, Florida Gastroenterology Society
2014 Fellow Award, Gastroenterology Research Group and the American Gastroenterology Association
2015 Poster of distinction, Digestive Disease Week
2015 Presidential Poster, ACG Annual Meeting
2016 Medical College of Wisconsin Career Development Award , Medical College of Wisconsin
2016 Young Investigator Award , American Gastroenterology Association
10/2017 IBD Abstract Award, American College of Gastroenterology
2017 Presidential poster, World Congress of Gastroenterology annual meeting
United European Gastroenterology Congress Award 2019

MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES:
2008 - Present American College of Physicians (Member)
2008 - Present American College of Gastroenterology (Member)
2010 - Present American Gastroenterology Association (Member)
2013 - Present American College of Gastroenterology "Minority Affairs and Cultural Diversity Committee" (Member)
2014 - Present Crohn's and Colitis Foundation of America (Member)

EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS:
Editorship
2013 - 2015 American College of Gastroenterology Case Report Journal
Journal Review
Digestive Disease Science
European Journal of Gastroenterology & Hepatology
Journal of Crohn's and Colitis
American Journal of Gastroenterology
Endocrine Connections
Gastroenterology
Drugs
British Medical Journal
Inflammation Research
Clinical Pharmacokinetics
World Journal of Gastroenterology
Inflammatory Bowel Disease Journal
Alimentary Pharmacology & Therapeutics
Ad-Hoc Reviewer
2018 Abstract reviewer, Department of Medicine Research Retreat, Medical College of Wisconsin
2018 Abstract reviewer, Annual Meeting of the American College of Gastroenterology, American College of Gastroenterology
2018 Abstract reviewer, Digestive Disease Week 2018 - Category: Therapeutic drug monitoring in Inflammatory Bowel Diseases, American Gastroenterology Association
Medical grant reviewer, Dutch Organization for Health Research and Development (ZonMw)
Medical grant reviewer, Digestive Disease Center Medical College of Wisconsin

RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS:
Active
Peer Review
Title:
Development of a Mucosal Healing Test in Patients with inflammatory bowel diseases
Source:
Prometheus Labs
Role:
Primary Investigator
Dates:
02/15/2016 - Present
 
Title:
Association of vedolizumab drug levels and anti-vedolizumab antibodies and inflammatory bowel disease remission in patients with inflammatory bowel diseases
Source:
Prometheus Labs
Role:
Primary Investigator
Dates:
04/06/2016 - Present
 
Title:
Tacrolimus in combination with vedolizumab Vs vedolizumab monotherapy in the treatment of moderate to severe ulcerative colitis: A randomized controlled trial.
Source:
Takeda American Research and Development Center
Role:
Primary Investigator
PI:
Yarur, Andres
Dates:
12/01/2016 - Present
 
Title:
Baseline Cytokine Profile and Response to Ustekinumab Therapy In Crohn’s Disease (FORSEE Study)
Source:
Internal funds – AGA Grant submitted
Role:
Primary Investigator
Dates:
03/30/2017 - Present
 
Title:
The association between body composition and response to therapy in inflammatory bowel disease patients.
Source:
Digestive Disease Center, Medical College of Wisconsin
Role:
Primary Investigator
PI:
Yarur, Andres
Dates:
04/01/2017 - Present
 
Title:
Using a Tablet Based Application to Streamline Clinic Work Flow and Enhance Patient Satisfaction
Source:
Clinical & Translational Science Institute
Role:
Co-Investigator
Dates:
06/21/2017 - Present
 
Title:
Association of ustekinumab drug levels and anti-vedolizumab antibodies and inflammatory bowel disease remission in patients with inflammatory bowel diseases.
Source:
Prometheus Laboratories
Role:
Co-Investigator
Dates:
09/01/2017 - Present
 
Title:
Development of mass cytometry as a tool for vedolizumab mechanism of action in studies involving patients with inflammatory bowel diseases
Source:
Takeda American Research and Development Center
Role:
Co-Investigator
Dates:
09/01/2017 - Present
 
Prior
Peer Review
Title:
Association between fistula healing in Crohn’s disease and the pharmacokinetics of infliximab
Source:
Faculty development fund award. Medical College of Wisconsin
Role:
Primary Investigator
Dates:
09/01/2016 - 12/01/2016
 

INVITED LECTURES/WORKSHOPS/PRESENTATIONS:
Local
Yarur, A, Updates in Inflammatory Bowel Diseases, IBD Update, Milwaukee, WI, 03/12/2016
Therapeutic Drug Monitoring, Updates in IBD, Medical College of Wisconsin, Milwaukee, WI, 03/2016
Why haven’t we found the cure for IBD?, MCW Patient IBD Program, Medical College of Wisconsin, Milwaukee, WI, 03/2016
Updates in Inflammatory Bowel diseases, Medicine Grand Rounds, Medical College of Wisconsin, Milwaukee, WI, 03/2016
Extraintestinal Complications of IBD, State of the Gut, Medical College of Wisconsin, Milwaukee, WI, 09/2016
Inflammatory Diseases of the Small Bowel and Colon, Medical College of Wisconsin, Milwaukee, WI, 11/2016
What is IBD?, IBD Program, Carroll University, Waukesha, WI, 11/2016
Biosimilars, Crohn’s and Colitis Foundation of America patient education program, Milwaukee, WI, 12/2016
Dysplasia and colo-rectal cancer in inflammatory bowel diseases, Updates in IBD, Medical College of Wisconsin, Milwaukee, WI, 03/2017
Crohn’s and Colitis, Crohn’s and Colitis Foundation IBD program, Carroll University, Waukesha, WI, 10/2017
 
Regional
IBD in the elderly: Can we use the same medications?, • Crohn’s and Colitis Foundation of America Illinois provider education program, Chicago, IL, 03/2017
WHAT IS THE BEST THERAPY FOR MY CROHN’S DISEASE? STATE OF THE ART TREATMENT IN CROHN’S DISEASE, Crohn's & Colitis Conference, Medical College of Wisconsin - Milwaukee, WI, 05/12/2018 - Present
Are There Specific Concerns I Should Be Aware of as I Get Older with IBD?, Crohn's & Colitis Conference, Milwaukee, WI, 05/11/2019
 
National
Yarur A, Sussman D, Deshpande A, Rueda S, Salem M, Rueda M, Abreu M, Prognostic Factors for Post-surgical Complications in Inflammatory Bowel Diseases: A Novel Predictive Score, American College of Gastroenterology, Washington, D.C., 2011
Yarur AJ, Deshpande AR, Mandalia AB, Dauer RM, Czul F, Sussman DA, Abreu MT, Does abdomino-pelvic CT done during emergency department visit affect management in patients with inflammatory bowel diseases?, American College of Gastroenterology Annual Meeting, Las Vegas, NV, 2012
Yarur AJ, Deshpande AR, Mandalia AB, Dauer RM, Czul F, Abreu MT, Sussman DA, Amylase and lipase significance in the evaluation of acute gastrointestinal symptoms in patients with inflammatory bowel disease, Florida Gastroenterology Society Meeting, Boca Raton, FL, 2012
Yarur AJ, Hauenstein S, Sussman DA, Barkin JS, Deshpande AR, Quintero MA, Lockton S, Singh S, Abreu MT, Correlation Of Intestinal Tissue Anti-TNF Drug Levels With Endoscopic Disease Activity In Patients With Inflammatory Bowel Disease: The ATLAS Study, American College of Gastroenterology Annual Meeting, San Diego, CA, 2013
Yarur AJ, Hauenstein S, Lockton S, Barkin J, Singh S, Abreu MT, Serum adalimumab levels and antibodies correlate with endoscopic intestinal inflammation and inflammatory markers in patients with inflammatory bowel disease, Florida Gastroenterology Society Annual Meeting, Orlando, FL, 2013
Yarur AJ, Drake K, Kubiliun M, Ryan D, Sussman DA, Hauenstein S, Quintero MA, Singh S, Barkin MA, Abreu MT, Higher 6-Thioguanine Nucleotide Concentrations Are Associated With Higher Trough Levels Of Infliximab In Patients On Combination Therapy, Digestive Disease Week, Chicago, IL, 05/2014
Yarur AJ, Quintero MA, Jain A, Abreu MT, Serum amyloid A is an accurate biomarker for mucosal and histologic inflammation in patients with inflammatory bowel disease, American College of Gastroenterology Annual Meeting, Honolulu, HI, 10/20/2015
Yarur AJ, Wichmann A, Hirsch A, Rubin DT, Fecal calprotectin levels can predict pharmacokinetics of anti-TNF therapy, American College of Gastroenterology Annual Meeting, Honolulu, HI, 10/20/2015
 
International
Segovia R, Benavente D, Zamarin J, Diaz O, Yarur A, Bramh J, Silva G, Buckel E, Ferrario M, Uribe M, Godoy J, Analyzing patient with hepatitis C for liver transplantation, Chilean Transplant Conference, Santiago, Chile, 2006
Statistical survival analysis of Patients with Liver Transplantation and Hepatitis C Infection, National Internal Medicine Conference, Valparaiso, Chile, 2006
Segovia R; Castro L, Yarur A; Roblero JP/Presenter: Roblero JP, Use of Everolimus as inmunosupresor in patients with a liver transplant and renal failure, Pan-American Gastroenterology Conference, Santiago, Chile, 2008
Vedolizumab vs anti-TNF in biologic-naive uc-patients, ECCO 2019, Copenhagen, Denmark
 

COMMITTEE SERVICE:
Medical College
2011 - 2014 Member, Selection Committee for the Internal Medicine Residency Program, University of Miami
2013 - 2016 Member, Minority Affairs and Cultural Diversity Committee, American College of Gastroenterology
2016 - Present Member, Publications Committee, American College of Gastroenterology
2016 - Present Member, Gastroenterology Fellow training Committee, Medical College of Wisconsin
 
Hospital
2011 - 2014 Member, Selection Committee for Internal Medicine Residency Program, Medicine, Internal Medicine, University of Miami
 

MEDICAL COLLEGE TEACHING ACTIVITIES:
Medical Student Education
2015 - Present Preceptor - Internal Medicine Outpatient Rotation
 
Resident and Fellow Education
11/30/2016 Academic Half Day Lecture: Small Bowel and Colon Inflammatory Conditions
 

EXTRAMURAL TEACHING:
Medical Student Education
2011 - 2014 University of Miami, Instructor at the Gastroenterology Module
 

LANGUAGES:
English, Spanish


BIBLIOGRAPHY
Refereed Journal Publications/Original Papers
1. Yarur A, Castro L, Segovia R, Roblero JP, Uribe M, Ferrario M, Buckel E. Small for Size Syndrome as complication of Liver Transplant. Rev Med Chile 2009; 137: 927-931. PMID: 19802420
2. Castro L, Yarur A, Segovia R, Ponce R, Uribe M, Ferrario M, Buckel E, Iturriaga H. Acommodation process: ABO-incompatible liver transplantation. Rev Med Chile 2009; 137: 1055-1059. PMID: 19915771
3. Yarur AJ, Deshpande AR, Pechman DM, Tamariz L, Abreu MT, Sussman DA. Inflammatory bowel disease is associated with an increased incidence of cardiovascular events. Am J Gastroenterol. 2011 Apr;106(4):741-7.
4. Yarur AJ, Strobel SG, Deshpande AR, Abreu MT. Predictors of aggressive inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2011 Oct;7(10):652-9. PMCID: PMC3265007
5. Brito JP, Yarur AJ, Prokop LJ, McIver B, Murad MH, Montori VM. Prevalence of thyroid cancer in multinodular goiter versus single nodule: a systematic review and meta-analysis. Thyroid. 2013 Apr;23(4):449-55.
6. Yarur AJ, Abreu MT, Salem MS, Deshpande AR, Sussman DA. The impact of Hispanic ethnicity and race on post-surgical complications in patients with inflammatory bowel disease. Dig Dis Sci. 2014 Jan;59(1):126-34.
7. Panara AJ, Yarur AJ, Rieders B, Proksell S, Deshpande AR, Abreu MT, Sussman DA. The incidence and risk factors for developing depression after being diagnosed with inflammatory bowel disease: a cohort study. Aliment Pharmacol Ther. 2014 Apr;39(8):802-10.
8. Yarur AJ, Abreu MT, Deshpande AR, Kerman DH, Sussman DA. Therapeutic drug monitoring in patients with inflammatory bowel disease. World J Gastroenterol. 2014 Apr 07;20(13):3475-84. PMCID: PMC3974514
9. Panara AJ, Yarur AJ, Sussman DA. Letter: psychological remission - a future endpoint in inflammatory bowel disease? Authors' reply. Aliment Pharmacol Ther. 2014 Jun;39(12):1436-7.
10. Yarur AJ, Mandalia AB, Dauer RM, Czul F, Deshpande AR, Kerman DH, Abreu MT, Sussman DA. Predictive factors for clinically actionable computed tomography findings in inflammatory bowel disease patients seen in the emergency department with acute gastrointestinal symptoms. J Crohns Colitis. 2014 Jun;8(6):504-12.
11. Berry AC, Herdes RE, Larsen MF, Yarur AJ, Scolapio JS, Patel BB, Avalos D, Lenchus JD, Reuther III WL. An atypical presentation of small bowel metastasis from a previously undiagnosed primary lung adenocarcinoma. J Med Cases. 2014;5(9):511-514.
12. Panara AJ, Yarur AJ, Sussman DA. Letter: is there a bi-directional relationship between depression and IBD? Authors' reply. Aliment Pharmacol Ther. 2014 Jul;40(2):214.
13. Yarur AJ, Abreu MT. Back to the beginning: restarting infliximab in inflammatory bowel disease patients with prior loss of response. Clin Gastroenterol Hepatol. 2014 Sep;12(9):1482-4.
14. Yarur AJ, Czul F, Levy C. Hepatobiliary manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2014 Sep;20(9):1655-67.
15. Yarur AJ, Kubiliun MJ, Czul F, Sussman DA, Quintero MA, Jain A, Drake KA, Hauenstein SI, Lockton S, Deshpande AR, Barkin JS, Singh S, Abreu MT. Concentrations of 6-thioguanine nucleotide correlate with trough levels of infliximab in patients with inflammatory bowel disease on combination therapy. Clin Gastroenterol Hepatol. 2015 Jun;13(6):1118-24.e3.
16. Yarur AJ, Jain A, Sussman DA, Barkin JS, Quintero MA, Princen F, Kirkland R, Deshpande AR, Singh S, Abreu MT. The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study. Gut. 2016 Feb;65(2):249-55.
17. Simian D, Estay C, Kronberg U, Yarur A, Castro M, Lubascher J, Acuña R, Quera R. Differences by age in clinical features of inflammatory bowel disease. Rev Med Chil. 2015;143(6):689-96.
18. Yarur AJ, Rubin DT. Therapeutic Drug Monitoring of Anti-tumor Necrosis Factor Agents in Patients with Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2015 Jul;21(7):1709-18.
19. Calmet FH, Yarur AJ, Pukazhendhi G, Ahmad J, Bhamidimarri KR. Endoscopic and histological features of mycophenolate mofetil colitis in patients after solid organ transplantation. Ann Gastroenterol. 2015 Jul-Sep;28(3):366-373. PMCID: PMC4480174
20. Corral JE, Yarur AJ, Diaz L, Simmons OL, Sussman DA. Cross-sectional analysis of patient phone calls to an inflammatory bowel disease clinic. Ann Gastroenterol. 2015 Jul-Sep;28(3):357-365. PMCID: PMC4480173
21. Hirsch A, Yarur AJ, Dezheng H, Rodriquez D, Krugliak Cleveland N, Ali T, Hurst RD, Umanskiy K, Hyman N, Colwell J, Rubin DT. Penetrating Disease, Narcotic Use, and Loop Ostomy Are Associated with Ostomy and IBD-related Complications After Ostomy Surgery in Crohn's Disease Patients. J Gastrointest Surg. 2015 Oct;19(10):1852-61.
22. Yarur AJ, Jain A, Hauenstein SI, Quintero MA, Barkin JS, Deshpande AR, Sussman DA, Singh S, Abreu MT. Higher adalimumab levels are associated with histologic and endoscopic remission in patients with Crohn’s disease and ulcerative colitis. Inflamm Bowel Dis. 2015. In press.
23. Yarur AJ, Jain A, Hauenstein SI, Quintero MA, Barkin JS, Deshpande AR, Sussman DA, Singh S, Abreu MT. Higher Adalimumab Levels Are Associated with Histologic and Endoscopic Remission in Patients with Crohn's Disease and Ulcerative Colitis. Inflamm Bowel Dis. 2016 Feb;22(2):409-15.
24. Yarur AJ, Gondal B, Hirsch A, Christensen B, Cohen RD, Rubin DT. Higher Thioguanine Nucleotide Metabolite Levels are Associated With Better Long-term Outcomes in Patients With Inflammatory Bowel Diseases. J Clin Gastroenterol. 2018 07;52(6):537-544.
25. Yarur AJ, Kanagala V, Stein DJ, Czul F, Quintero MA, Agrawal D, Patel A, Best K, Fox C, Idstein K, Abreu MT. Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn's disease. Aliment Pharmacol Ther. 2017 04;45(7):933-940.
26. Yarur AJ, Jain A, Quintero MA, Czul F, Deshpande AR, Kerman DH, Abreu MT. Inflammatory Cytokine Profile in Crohn’s Disease Non-Responders to Optimal Anti-Tumor Necrosis Factor Therapy. J Clin Gastroenterol. In Press.
27. Patel P, Yarur AJ, Dalal S, Sakuraba A, Rubin DT, Hanauer SB, Hanan I, Raffals LH, Cohen R, Pekow J. Clinical Response and Complications are not Associated with Drug Levels in Patients with Severe Ulcerative Colitis on IV Ciclosporin Induction Therapy. Inflamm Bowel Dis. 2018. In Press.
28. Christensen B, Micic D, Gibson PR, Yarur AJ, Bellaguarda E, Corsello P, Gaetano JN, Kinnucan J, Rao VL, Reddy S, Singh S, Pekow J, Rubin DT. Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease. Aliment Pharmacol Ther. 2018 Mar;47(6):753-762.
29. Micic D, Yarur AJ, Gonsalves A, Rao VL, Broadaway S, Cohen RD, Dalal S, Gaetano JN, Glick LR, Hirsch A, Pekow J, Sakuraba A, Walk ST, Rubin DT. Risk factors for Clostridium difficile isolation in inflammatory bowel disease: a prospective study. Digestive Diseases and Sciences 2018. In Press.
30. Yarur AJ, Gondal B, Hirsch A, Christensen B, Cohen RD, Rubin DT. Higher Thioguanine Nucleotide Metabolite Levels are Associated With Better Long-term Outcomes in Patients With Inflammatory Bowel Diseases. J Clin Gastroenterol. In Press
31. Yarur AJ, Jain A, Quintero MA, Czul F, Deshpande AR, Kerman DH, Abreu MT. Inflammatory Cytokine Profile in Crohn's Disease Nonresponders to Optimal Antitumor Necrosis Factor Therapy. J Clin Gastroenterol. 2019 Mar;53(3):210-215. PMCID: PMC6127004
32. Yarur AJ, Quintero MA, Jain A, Czul F, Barkin JS, Abreu MT. Serum Amyloid A as a Surrogate Marker for Mucosal and Histologic Inflammation in Patients with Crohn's Disease. Inflamm Bowel Dis. 2017 01;23(1):158-164.
33. Yarur AJ, Bruss A, Naik S, Beniwal-Patel P, Fox C, Jain A, Berens B, Patel A, Ungaro R, Bahur B, Dubinsky M, Stein DJ. Vedolizumab Concentrations Are Associated with Long-Term Endoscopic Remission in Patients with Inflammatory Bowel Diseases. Dig Dis Sci. 2019 06;64(6):1651-1659.
34. Pérez-Jeldres T, Tyler CJ, Boyer JD, Karuppuchamy T, Yarur A, Giles DA, Yeasmin S, Lundborg L, Sandborn WJ, Patel DR, Rivera-Nieves J. Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists. Front Pharmacol. 2019;10:212. PMCID: PMC6425155
35. Micic D, Yarur A, Gonsalves A, Rao VL, Broadaway S, Cohen R, Dalal S, Gaetano JN, Glick LR, Hirsch A, Pekow J, Sakuraba A, Walk ST, Rubin DT. Correction to: Risk Factors for Clostridium difficile Isolation in Inflammatory Bowel Disease: A Prospective Study. Dig Dis Sci. 2018 10;63(10):2815.
36. Christensen B, Gibson PR, Micic D, Colman RJ, Goeppinger SR, Kassim O, Yarur A, Weber CR, Cohen RD, Rubin DT. Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2019 02;17(3):486-493.
37. Christensen B, Colman RJ, Micic D, Gibson PR, Goeppinger SR, Yarur A, Weber CR, Cohen RD, Rubin DT. Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety. Inflamm Bowel Dis. 2018 03 19;24(4):849-860. PMCID: PMC6196763
38. Patel P, Yarur A, Dalal S, Sakuraba A, Rubin DT, Hanauer SB, Hanan I, Raffals LH, Cohen RD, Pekow J. Clinical Response and Complications are not Associated with Drug Levels in Patients with Severe Ulcerative Colitis on IV Cyclosporine Induction Therapy. Inflamm Bowel Dis. 2018 05 18;24(6):1291-1297.
39. Micic D, Yarur A, Gonsalves A, Rao VL, Broadaway S, Cohen R, Dalal S, Gaetano JN, Glick LR, Hirsch A, Pekow J, Sakuraba A, Walk ST, Rubin DT. Risk Factors for Clostridium difficile Isolation in Inflammatory Bowel Disease: A Prospective Study. Dig Dis Sci. 2018 04;63(4):1016-1024.
40. Christensen B, Micic D, Gibson PR, Yarur A, Bellaguarda E, Corsello P, Gaetano JN, Kinnucan J, Rao VL, Reddy S, Singh S, Pekow J, Rubin DT. Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease. Aliment Pharmacol Ther. 2018 Mar;47(6):753-762. PMCID: PMC5821055
41. Simian D, Estay C, Kronberg U, Yarur A, Castro M, Lubascher J, Acuña R, Quera R. [Differences by age in clinical features of inflammatory bowel disease]. Rev Med Chil. 2015 Jun;143(6):689-96.
42. Ungaro RC, Yarur A, Jossen J, Phan BL, Chefitz E, Sehgal P, Kamal K, Bruss A, Beniwal-Patel P, Fox C, Patel A, Bahur B, Jain A, Stein D, Naik S, Dubinsky MC. Higher Trough Vedolizumab Concentrations During Maintenance Therapy are Associated With Corticosteroid-Free Remission in Inflammatory Bowel Disease. J Crohns Colitis. 2019 Aug 14;13(8):963-969.
 
Books, Chapters, and Reviews
1. Yarur AJ, Kane S. Pregnancy in patients with inflammatory bowel diseases. A review article. Dig Liver Dis. 2013;45(10):787-94.
2. American Gastroenterological Association Institute Clinical Handbook in Gastroenterology (Castle Connolly Graduate Board Review). 6th edition- Chapter 5 (Inflammatory Bowel Disease). Authors: David H. Kerman, Andres J. Yarur, Maria T. Abreu
 
Non-Refereed Journal Publications/Original Papers
1. Yarur AJ. Use of capsule endoscopy as a diagnostic and monitoring tool in Crohn’s disease. GI Fellow Advisor. Vol. 6, Issue 1. May of 2006.
2. Micic D, Yarur AJ, Rubin DT. Biologic Therapies for Inflammatory Bowel Diseases. The New Gastroenterologist. Summer 2015.
 
Abstracts
1. Segovia R, Zamarin J, Yarur A, Bramh J, Silva G, Buckel E, Ferrario M, Uribe M, Godoy J. Presenter: Segovia R. (2003, November). Acute and Chronic Renal Dysfunction in patients with a liver transplant. Poster presented at the 2003 Gastroenterology Chilean Conference (Valparaiso, Chile).
2. Yarur A, Hormazabal M, Kramer V, Marin J. Presenter: Yarur A. (2005, December). Prevalence of allelic variants in the cytochrome P450 among Chilean population. Poster presented at the 2005 Chilean Pharmacology Conference (Santiago, Chile).
3. Segovia R, Poblete JP, Yarur A, Zamarin J. Presenter: Poblete JP. (2006, December). Liver Transplant Experience in San Borja Arriaran Hospital. Poster presented at the 2006 Chilean Hepatology Conference (Valparaiso, Chile).
4. Statistical survival analysis of Patients with Liver Transplantation and Hepatitis C Infection, National Internal Medicine Conference, Valparaiso, Chile, 2006
5. Segovia R, Benavente D, Zamarin J, Diaz O, Yarur A, Bramh J, Silva G, Buckel E, Ferrario M, Uribe M, Godoy J, Analyzing patient with hepatitis C for liver transplantation, Chilean Transplant Conference, Santiago, Chile, 2006
6. Zamarin J, Yarur A, Diaz O, Brizzolara A, Fasce G. Presenter: Yarur A. (2006, December). Depression in the Elderly: Relationship with Functionality, Nutritional Condition and Other Pathologies. Poster presented at the 2006 Chilean Internal Medicine Conference (Santiago, Chile).
7. Segovia R; Castro L, Yarur A; Roblero JP/Presenter: Roblero JP , Use of Everolimus as inmunosupresor in patients with a liver transplant and renal failure, Pan-American Gastroenterology Conference, Santiago, Chile, 2008
8. Yarur A, Brown T, Reddy C, Schiff E. Presenter: Yarur A. (2009, December). Overlap of porto-pulmonary and hepato-pulmonary syndromes. Poster presented at the 2009 American College of Gastroenterology meeting (San Diego, CA).
9. Yarur A, Sussman D, Deshpande A, Tamariz L, Palacios A, Damas O, Jahann D, Abreu M/Presenter: Yarur A. (2009, October). Cardiovascular Events and Risk Factors in Inflammatory Bowel Disease. Poster presented at the 2009 American College of Gastroenterology meeting (San Diego, CA).
10. Yarur A, Sussman D, Deshpande A, Damas O, Abreu M/Presenter: Yarur A. (2009, December). Ten-Year Coronary Heart Disease Risk among IBD Patients. Poster presented at the 2009 Crohn and Colitis foundation of America Meeting (Hollywood, FL).
11. Brito JP, Yarur A, Sabharwal A, Solorzano C. Multinodular Goiter with Obstruction Symptoms. Should we look for cancer? Presented at the 2010 ENDO society Meeting, (San Diego, CA).
12. Yarur A, Brito JP, Sussman D, Deshpande A, Pechman D, Sabharwal A. Abreu M. Inflammatory bowel disease has a beneficial effect on glucose metabolism in diabetes. Presented at the 2010 American College of Gastroenterology meeting (San Antonio, TX).
13. Kummerfeldt C, Yarur A, Brito JP, Parraga R, Zeitouni J, Garcia-Buitrago M, Ghanta R, Martin P. Acute viral hepatitis A inducing autoimmune hepatitis and exacerbation of chronic hepatitis B. Presented at the 2010 American College of Gastroenterology meeting, (San Antonio, TX).
14. Yarur A, Sussman D, Deshpande A, Pechman D, Gutierrez J. Abreu M. Inflammatory bowel disease increase incidence of stroke. Presented at the 2010 Crohn’s and Colitis foundation society. (Hollywood, FL).
15. Yarur AJ, Sussman DA, Deshpande AR, Tamariz L, Pechman DM, Palacio AM, Abreu MT. Inflammatory Bowel Disease Increases the Incidence of Coronary Artery Disease. May 2010 Gastroenterology, Vol. 138, Issue 5, S-201
16. Czul F, Yarur A, Levi C, Martin P. Comparison of MELD and MELD-Na as predictor of mortality after a TIPS procedure. Presented at the 2011 American College of Gastroenterology meeting (Washington D.C.)
17. Yarur AJ, Sussman DA, Deshpande AR, Pechman DM, Czul F, Rueda S, Abreu MT. Neutrophil-to-Lymphocyte Ratio as a Predictor of Surgical Complications in Inflammatory Bowel Disease. May 2011 Gastroenterology, Vol. 140, Issue 5, S-436
18. Czul F, Yarur A, Levy C, Rueda S, Martin P. Serum Alfa-Feto Protein Level Does Not Predict Micro-Vascular Invasion in Patients Undergoing Orthotopic Liver Transplantation for Hepatocellular Carcinoma. May 2011 Gastroenterology, Vol. 140, Issue 5, S-925
19. Proksell S, Yarur AJ, Sussman DA, Panara AJ, Rideres B, Abreu MT, Desphande AR. Do Hispanics receive the same medical treatment for inflammatory bowel disease as non-Hispanics? Abstract presented the American College of Gastroenterology meeting national meeting 2012 (Las Vegas, NV).
20. Czul F, Yarur AJ, Deshpande AR, Sussman DA, Abreu MT. Diagnosis of Crohn’s disease after age 60 is associated with lower prevalence of penetrating phenotype. Abstract presented at the American College of Gastroenterology meeting national meeting 2012 (Las Vegas, NV).
21. Rieders B, Yarur AJ, Kerman DH. Recurrent severe dysphagia secondary to a siliconoma after breast implant failure. Abstract presented at the American College of Gastroenterology meeting national meeting 2012 (Las Vegas, NV).
22. Yarur AJ, Abreu MT, Salem M, Proksell S, Pechman DM, Sussman DA, Deshpande AR. Surgical Procedures and Outcomes in the Hispanic Population With Inflammatory Bowel Disease. May 2012 Gastroenterology, Vol. 142, Issue 5, S-796–S-797
23. Yarur AJ, Rieders B, Kubilium M, Panara A, Salem M, Deshpande AR, Abreu MT, Sussman DA. Factors predicting high doses of sedation and incomplete colonoscopy among patients with inflammatory bowel diseases. Presented at the American College of Gastroenterology meeting national meeting 2013 (San Diego, CA).
24. Trivella JP, Yarur AJ, Deshpande R, Abreu MT, Sussman DA. Clinical response to infliximab after secondary failure with adalimumab or certolizumab pegol in Crohn’s disease. Presented at the American College of Gastroenterology meeting national meeting 2013 (San Diego, CA).
25. Panara A, Yarur AJ, Rieders B, Proksell S, Deshpande AR, Abreu MT, Sussman DA. Psychiatric diseases in patients with inflammatory bowel diseases are not related to anemia, iron deficiency or inflammatory markers. Presented at the American College of Gastroenterology meeting national meeting 2013 (San Diego, CA).
26. Mandalia A, Yarur AJ, Dauer R, Deshpande AR, Abreu MT, Sussman DA. The yield for routine stool and colonic tissue studies in hospitalized patients with an Inflammatory Bowel Disease exacerbation. Presented at the American College of Gastroenterology meeting national meeting 2013 (San Diego, CA).
27. Castresana DN, Yarur AJ, Tamariz L, Bilsker M, Sussman DA. Electrocardiographic and Echocardiographic Endpoints: insights into cardiovascular damage in IBD. Presented at the American College of Gastroenterology meeting national meeting 2013 (San Diego, CA).
28. Salem M, Portillo M, Korc P, Yarur AJ, Shaker A. A Rare Case of Disseminated Coccidioides Immitis with Colonic Involvement. Presented at the American College of Gastroenterology meeting national meeting 2013 (San Diego, CA).
29. Yarur AJ, Kubilium M, Czul F, Deshpande R, Abreu MT, Sussman DA. Successful treatment with infliximab therapy among underserved individuals with inflammatory bowel disease. Presented at the American College of Gastroenterology meeting national meeting 2013 (San Diego, CA).
30. Corral JE, Yarur AJ, Diaz L, Garcia.Buitriago M, Sussman DA. A case of severe sprue-like enteropathy associated with olmesartan. Presented at the American College of Gastroenterology national meeting 2014.
31. Yarur AJ, Hauenstein S, Czul F, Lockton S, Quintero MA, Singh S, Barkin MA, Abreu MT. Serum Certolizumab pegol levels and antibodies-to-Certolizumab pegol are associated with C-reactive protein levels in patients with Crohn’s disease. Presented at the American College of Gastroenterology national meeting 2014.
32. Czul F, Yarur AJ, Bhamidimarri K. Vitamin B12 level could be a novel diagnostic marker to predict cirrhosis in patients with chronic liver disease. Presented at the American College of Gastroenterology national meeting 2014.
33. Yarur AJ, Mendez V, Liege D, Sussman DA. Do Optimal Anti-Tumor Necrosis Factor Levels Influence Vitamin D Levels or Metabolic Bone Disease in Patients With Inflammatory Bowel Diseases? Presented at the American College of Gastroenterology national meeting 2014.
34. Christensen B, Goeppinger SR, Colman RJ, Siddiqui D, Yarur A, Hirsch A, Bochenek AA, Wichmann A. The Efficacy and Safety of Calcineurin Inhibitors in Inducing and Maintaining Clinical Remission in IBD Patients Commencing Vedolizumab. April 2015 Gastroenterology, Vol. 148, Issue 4, S-866
35. Yarur, Kubiliun M, Drake K, Hauenstein S, Barkin JS, Sussman DA, Deshpande AR, Quintero MA. Higher 6-Thioguanine Nucleotide Concentrations Are Associated With Higher Trough Levels of Infliximab in Patients on Combination Therapy. May 2014 Gastroenterology, Vol. 146, Issue 5, S-134–S-135
36. Yarur A, Drake K, Kubiliun M, Dauer RM, Sussman DA, Jauenstein S, Quintero MA, Singh S. Anti-Tumor Necrosis Factor Levels Are Not Associated With Intestinal Extent of Mucosal Inflammation in Patients With Inflammatory Bowel Diseases. May 2014 Gastroenterology, Vol. 146, Issue 5, S-244
37. Yarur A, Trivella JP, Sussman DA, Drake K, Barkin JS, Hauenstein S, Deshpande AR, Quintero MA. Anti-Tumor Necrosis Factor Drug Levels and Anti-Bodies Are Associated With Crohn's Disease Recurrence At the Level of the Ileo-Colonic Anastomosis After Ileal Resection. May 2014 Gastroenterology, Vol. 146, Issue 5, S-243–S-244
38. Dauer RM, Yarur A, Abreu MT. Infliximab Re-Induction Outcomes After a Failure to Treatment. May 2013 Gastroenterology, Vol. 144, Issue 5, S-430
39. Czul F, Yarur A, Wall EA, Semrad CE. Low Albumin and Male Gender Predicts High Ileostomy Outputs in Patients Undergoing Ileostomy Creation. May 2013 Gastroenterology, Vol. 144, Issue 5, S-535–S-536
40. Yarur AJ, Salem MS, Deshpande AR, Brito JP, Abreu MT, Sussman DA. Evaluating the Adequacy of Race and Ethnicity Reporting and Representation in Published Randomized Controlled Trials Involving Patients With Inflammatory Bowel Disease. May 2013 Gastroenterology, Vol. 144, Issue 5, S-574
41. Yarur AJ, Panara AJ, Rieders B, Proksell S, Deshpande AR, Abreu MT, Sussman DA. The Incidence and Risk Factors for Developing Depression After Been Diagnosed With Inflammatory Bowel Disease: A Cohort Study. May 2013 Gastroenterology, Vol. 144, Issue 5, S-753
42. Yarur AJ, Deshpande AR, Sussman DA, Hauenstein S, Lockton S, Barkin JS, Singh S, Abreu MT. Serum Adalimumab Levels and Antibodies Correlate With Endoscopic Intestinal Inflammation and Inflammatory Markers in Patients With Inflammatory Bowel Disease. May 2013 Gastroenterology, Vol. 144, Issue 5, S-774–S-775
43. Trivella JP, Yarur A, Wong J, Sussman DA. The Value of Cross-Sectional Imaging to Detect Crohn's Disease Recurrence After Ileo-Colonic Anastomosis. May 2014 Gastroenterology, Vol. 146, Issue 5, S-432
44. Mendez V, Yarur A, Coronel E, Deshpande AR, Kerman DH, Abreu MT, Sussman DA. Inflammatory Bowel Disease and Vitamin D Deficiency in a Southern Climate. May 2014 Gastroenterology, Vol. 146, Issue 5, S-448–S-449
45. Trivella JP, Yarur AJ, Elden A, Mandalia A, Dauer RM, Sussman DA. The prevalence of sub-clinical sacroileitis in patients with inflammatory bowel disease. Presented at the American College of Gastroenterology national meeting 2014.
46. Corral JE, Yarur A, Diaz L, Simmons O, Sussman DA. Wake-Up Call -An Analysis of Patient Phone Calls to an Inflammatory Bowel Disease Clinic. May 2014 Gastroenterology, Vol. 146, Issue 5, S-379–S-380
47. Yarur A, Drake K, Jain A, Barkin JS, Hauenstein S, Kirkland R, Liu X, Quintero MA. Signaling Pathway Proteins Are Associated With Inflammation and Disease Location in IBD: Implications for Mucosal Healing and Malignancy Risk. May 2014 Gastroenterology, Vol. 146, Issue 5, S-827
48. Yarur A, Kubiliun M, Czul F, Coronel E, Deshpande AR, Abreu MT, Sussman DA. Incidence of Inflammatory Bowel Disease Complications in Black Patients: A Cohort Study. May 2014 Gastroenterology, Vol. 146, Issue 5, S-372–S-373
49. Yarur AJ, Gondal B, Syed N, Hirsch A, Christensen B, Cohen R, Rubin DT. Higher Thioguanine Metabolite Levels Improve Long-Term Outcomes in Patients With Inflammatory Bowel Diseases. Presented at ACG 2015.
50. Hirsch A, Yarur AJ, Nannegari V, Rubin DT. Risk Factors for Recurrent Crohn’s Disease After Creation of End Ileostomy. Presented at ACG 2015.
51. Christenssen B, Rubin DT, Goeppinger S, Colman RJ, Yarur AJ, Hirsch A, Bocheneck A, Wichmann A, Sakuraba A, Cohen R, Siddiqui D. Endoscopic and Histologic Response and Remission in Inflammatory Bowel Disease Patients Initiating Vedolizumab. Presented at ACG 2015.
52. Labbas J, Hirsch A, Yarur AJ, Rodriquez BA, Krugliak N, Rubin DT. Prevalence of Micronutrient Deficiencies in Patients With Crohn's Disease Undergoing Ostomy Creation. Presented at ACG 2015.
53. Yarur A, Gondal B, Syed N, Christnesen B, Hirsch A, Hyman N, Abreu MT. Validation of a Risk Score Predicting Post-Surgical Complications in Patients With Inflammatory Bowel Disease. April 2015 Gastroenterology, Vol. 148, Issue 4, S-832–S-833
54. Christensen B, Goeppinger SR, Colman RJ, Siddiqui D, Yarur A, BochenekAA, Wichmann A, Hirsch. Vedolizumab in the Treatment of IBD: The University of Chicago Experience. April 2015 Gastroenterology, Vol. 148, Issue 4, S-866
55. Dauer RM, Yarur A, Abreu MT. What Factors Influence Poor Bowel Preparations for Colonoscopies in Patients With Inflammatory Bowel Disease?. April 2015 Gastroenterology, Vol. 148, Issue 4, S-438
56. Christensen B, Goeppinger SR, Colman RJ, Siddiqui D, Yarur A, Hirsch A, Wichmann A, Boechenek AA. Crohn's Disease Patients Currently or Previously on Natalizumab Can Be Safely and Effectively Switched to Vedolizumab. April 2015 Gastroenterology, Vol. 148, Issue 4, S-866–S-867
57. Yarur AJ, Bruss A, Berens B, Fox C, Beniwal-Patel P, Patel A, Ungaro RC, Dubinsky M, Naik S, Stein D. Vedolizumab levels during induction are associated with long-term clinical and endoscopic remission in patients with inflammatory bowel disease. Presented at the European Crohn’s and Colitis Organization Congress 2018 (Vienna, Austria).
58. Yarur AJ, Bruss A, Jain A, Venkateswarlu K, Luna , Hester K, Patel A, Agrawal D, Fox, C, Werner S, Naik S, Stein D. Higher Vedolizumab Levels Are Associated with Deep Remission in Patients with Crohn’s Disease and Ulcerative Colitis on Maintenance Therapy with Vedolizumab. Presented at the European Crohn’s and Colitis Organization Congress 2017 (Barcelona, Spain).
59. Yarur AJ, Kanagala V, Stein D, Czul F, Agrawal D, Zadvornova Y, Quintero MA, Abreu MT. Higher Infliximab Trough Levels Are Associated With A Higher Rate Of Perianal Fistula Healing In Patients With Crohn’s Disease.
 Presented at the 2016 Digestive Disease Week (San Diego, California).
60. Yarur AJ, Bruss A, Berens B, Fox C, Beniwal-Patel P, Patel A, Ungaro RC, Dubinsky M, Naik S, Stein D. Vedolizumab levels during induction are associated with long-term clinical and endoscopic remission in patients with inflammatory bowel disease. Presented at the 2018 Digestive Disease Week (June of 2018).
61. Watson A, Yarur AJ. Rate and risk factors for post-operative complications in Crohn’s and colitis patients undergoing non-inflammatory bowel disease surgery. Presented at the 2018 Digestive Disease Week (June of 2018).
62. Watson A, Yarur AJ. Biologic drug discontinuation and tobacco use are independently associated with inflammatory bowel disease exacerbation after elective non-IBD related surgery. Presented at the 2018 Digestive Disease Week (June of 2018).
63. Baruah A, Yarur AJ, Aburajab M. Correlation between EUS-FNA and surgical specimen Ki67 for tumor grading in pancreatic neuroendocrine tumors. Presented at the 2018 Digestive Disease Week (June of 2018).
64. Baruah A, Yarur AJ, Aburajab M. Diagnostic yield and predictors of adequate cytology sampling for Ki67 on endoscopic ultrasound guided fine needle aspiration for grading of pancreatic neuroendocrine tumors. Presented at the 2018 Digestive Disease Week (June of 2018).
65. Daniel K, Yarur AJ, Dan-Yu G, Aburajab M. Outcome of transesophageal echocardiogram in patients with liver cirrhosis and the utility of pre-procedural endoscopic evaluation: a single-center experience. Presented at the 2018 Digestive Disease Week (June of 2018).
66. Bader H, Seymour L, Grady J, Stein D, Yarur AJ. Baseline UCEIS and Endoscopic Mayo Score Perform Similarly Predicting Response to Medical Therapy in Patients with Ulcerative Colitis. Presented at the 2018 MCW Department of Medicine retreat (March of 2018).
67. Yarur AJ, Bruss A, PateL A, Beniwal-Patel P, Fox C, Ungaro R, Dubinsky M, Naik S, Stein D. Vedolizumab Levels During Induction Are Associated with Remission in Patients with Inflammatory Bowel Diseases. Presented at the 2017 World Congress of Gastroenterology annual conference (October of 2017).
68. Dulai P, Boland BS, Vermeire S, D’Haens G, Laharie D, Afif, W, Yarur AJ, Savarino, E, Ho, J, Hester K, Kondragunta V, Hale M, Jain A and Sandborn W. A Non-invasive Serological Test to Assess the Efficacy of Biologic and Non-biologic Therapies on the Mucosal Health of Patients with Crohn’s Disease. Presented at the 2017 World Congress of Gastroenterology annual conference (October of 2017).
69. Yarur AJ, Bruss A, Jain A, Venkateswarlu K, Luna , Hester K, Patel A, Agrawal D, Fox, C, Werner S, Naik S, Stein D. Higher Vedolizumab Levels Are Associated with Deep Remission in Patients with Crohn’s Disease and Ulcerative Colitis on Maintenance Therapy with Vedolizumab. Presented at the 2017 Digestive Disease Week (Chicago, Illinois).
70. Yarur AJ, Jain A, Quintero MA, Abreu MT. Inflammatory Cytokines in Patients with Inflammatory Bowel Diseases That Don’t Respond to Optimal Anti-Tumor Necrosis Factor Therapy. Presented at the 2016 American College of Gastroenterology annual meeting.
71. Patel P, Yarur AJ, Pekow J. Clinical Response and Complications Are Not Associated with Level of Cyclosporine in Patients with Severe Ulcerative Colitis. Presented at the 2016 American College of Gastroenterology annual meeting.
72. Kanagala V, Stein D, Naik S, Agrawal D, Patel A, Best K, Fox C, Idstein K, Yarur AJ. Testing Serum Infliximab and Serum Antibodies to Infliximab with a Drug Tolerant Assay Has a Significant Effect on Clinical Decision Making in the Treatment of Patients with Inflammatory Bowel Diseases. Presented at the 2016 American College of Gastroenterology annual meeting.
73. Micic D, Gaetano JN, Gonsalves A, Broadaway S, Hirsch A, Yarur AJ, Cohen R, Dalal S, Pekow J, Sakuraba A, Walk S, Rubin DT. Crohn’s Disease, Antibiotic Use, and Recent Health Care Exposures Are Associated with Clostridium Difficile Isolation in IBD. Presented at the 2016 American College of Gastroenterology annual meeting.
74. Patricio Ibañez, Suzanne Devkota, rodrigo quera, Daniela Simian, Mauricio Moreno, Andres J. Yarur, Jaime Fernando Lubascher, Udo Kronberg, Carolina Figueroa, Gonzalo Pizarro, lilian flores. Abnormalities in the Fecal Microbiome of Patients with Ulcertative Colitis based on Length of Diagnosis and Disease Activity. Presented at the 2019 Digestive Disease Week (May of 2019).
75. Anish P, Fenster M, Bader G, Dimopoulos C, Deepak P, Ungaro RC, Ciorba MA, Yarur AJ, Hirten R, Christohi GP, Khatiwada A, Lin B, Colombel JF, Ha C, Cohen BL, Pekow JR, Beniwal-Patel P, Syal G. Real-World Effectiveness of Tofacitinib in Ulcerative Colitis; A Multi-Center Study. Poster Presented at Digestive Disease Week. May 2019, San Diego, CA
 

jenkins-FCD Prod-410 e9586552fe7f53c71f7923aa6e27aeabbd3c2473